$3.33 -0.17 (%) AcelRx Pharmaceuticals Inc - NASDAQ

Aug. 24, 2016 | 04:00 PM

Partner Headlines

  1. AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones for Product Portfolio

    Benzinga | Jan. 10, 2016 | 08:04AM EST
  2. Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide

    Benzinga | Dec. 22, 2015 | 12:20PM EST
  3. AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

    Benzinga | Nov. 19, 2015 | 07:09AM EST
  4. AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

    Benzinga | Nov. 4, 2015 | 07:07AM EST
  5. AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso

    Benzinga | Oct. 8, 2015 | 07:04AM EST
  6. AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain

    Benzinga | Oct. 6, 2015 | 07:07AM EST
  7. Morning Market Gainers

    Benzinga | Sep. 21, 2015 | 09:42AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 21, 2015 | 08:15AM EST
  9. Morning Market Gainers

    Benzinga | Sep. 9, 2015 | 09:39AM EST
  10. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 9, 2015 | 08:09AM EST
  11. Morning Market Losers

    Benzinga | Sep. 8, 2015 | 09:51AM EST
  12. 3 Catalysts To Watch Over The Next Couple Months For This Pharma Co.

    Benzinga | Sep. 2, 2015 | 11:18AM EST
  13. Morning Market Gainers

    Benzinga | Jul. 24, 2015 | 09:42AM EST
  14. Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain

    Benzinga | Jul. 2, 2015 | 07:02AM EST
  15. 7 Biotech Stocks Moving Off The UBS Healthcare Conference

    Benzinga | May. 19, 2015 | 14:16PM EST
  16. Morning Market Gainers

    Benzinga | May. 14, 2015 | 09:44AM EST
  17. Benzinga's Top #PreMarket Gainers

    Benzinga | May. 14, 2015 | 08:10AM EST
  18. US Stock Futures Surge Ahead Of Jobless Claims

    Benzinga | May. 14, 2015 | 07:14AM EST
  19. Morning Market Losers

    Benzinga | May. 5, 2015 | 09:57AM EST
  20. Benzinga's Top #PreMarket Losers

    Benzinga | May. 5, 2015 | 08:21AM EST
  21. Bill Ackman Boosts Jarden; Nautilus Wins Big In After-Hours Trading

    Benzinga | May. 4, 2015 | 19:06PM EST
  22. AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO

    Benzinga | Dec. 16, 2014 | 17:05PM EST
  23. Mid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike Higher

    Benzinga | Nov. 11, 2014 | 15:17PM EST
  24. Mid-Morning Market Update: Markets Edge Lower; D.R. Horton Posts Downbeat Profit

    Benzinga | Nov. 11, 2014 | 10:35AM EST
  25. AcelRx Pharmaceuticals Receives International Standards Organization Certification Of Its Quality Management System

    Benzinga | Nov. 10, 2014 | 07:09AM EST
  26. AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting

    Benzinga | Oct. 27, 2014 | 07:40AM EST
  27. Nike Jumps On Strong Results; Powell Industries Shares Slide

    Benzinga | Sep. 26, 2014 | 13:04PM EST
  28. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 26, 2014 | 10:07AM EST
  29. Morning Market Losers

    Benzinga | Sep. 26, 2014 | 09:45AM EST
  30. Benzinga's Top #PreMarket Losers

    Benzinga | Sep. 26, 2014 | 08:08AM EST
  31. AcelRx falls on FDA rejection

    IBD | Jul. 28, 2014 | 18:49PM EST
  32. AcelRx Pharma Plunges After FDA Rejects Device

    IBD | Jul. 28, 2014 | 14:35PM EST
  33. Morning Market Losers

    Benzinga | Jul. 28, 2014 | 09:48AM EST
  34. AcelRX Selling Off Sharply On FDA Reexamination

    Benzinga | Jul. 28, 2014 | 09:15AM EST
  35. Benzinga's Top Downgrades

    Benzinga | Jul. 28, 2014 | 08:58AM EST
  36. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 28, 2014 | 08:19AM EST
  37. Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold

    Benzinga | Jul. 28, 2014 | 07:33AM EST
  38. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 25, 2014 | 08:13AM EST
  39. US Stock Futures Down In Pre-Market Trade

    Benzinga | Jul. 7, 2014 | 07:34AM EST
  40. Top Funds Like Facebook And Health Care Stocks

    IBD | Jan. 7, 2014 | 18:59PM EST
  41. AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO

    Benzinga | Dec. 16, 2013 | 07:52AM EST
  42. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data

    Benzinga | Dec. 13, 2013 | 07:33AM EST
  43. AcelRx Announces Zalviso NDA Accepted for Filing by FDA

    Benzinga | Dec. 2, 2013 | 07:34AM EST
  44. AcelRx Pharma Issues NDA for Zalviso, Submission Required Payment of $1.95M to FDA

    Benzinga | Sep. 30, 2013 | 07:35AM EST
  45. UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals on Numerous Potential Catalysts Ahead

    Benzinga | Aug. 13, 2013 | 08:41AM EST
  46. AcelRx Pharma Announces Exercise of Option to Buy Additional Shares

    Benzinga | Dec. 14, 2012 | 05:16AM EST
  47. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 7, 2012 | 01:10AM EST
  48. AcelRx Pharmaceuticals Prices 12.5M Share Offering at $3.31/Share

    Benzinga | Dec. 6, 2012 | 23:33PM EST
  49. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 5, 2012 | 00:09AM EST
  50. FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain

    Benzinga | Nov. 15, 2012 | 01:28AM EST
Trading Center